A new class of
“encrypted RNA” vaccines are being
developed where the RNA would piggyback
onto an existing wild virus and spread
from person to person without any
person’s knowledge or consent. Although
this may sound like science fiction, it
is far from it. Two companies involved
in this research have received millions
of dollars from the federal government.
A study using this technology on hamsters
and the SARS-Cov-2 virus
has already been completed and a Phase I
trial on humans is in the
works. ICAN’s attorneys
have already sent legal demands to all
government agencies involved.
 |
It seems the government
and the military are so enthused
about this new vaccine deployment
technology that Congress tucked a
law, the PREVENT
Pandemics Act, into the 2023
omnibus appropriations bill to
facilitate it. Among other things,
the Act has a section dedicated to
Platform
Technologies that supports
the “development and review of new
treatments and countermeasures
that use cutting-edge, adaptable
platform technologies that can be
incorporated or used in more than
one drug or biological product.”
|
This Act will also be used
to fund a new HHS government agency called
ARPA-H
(Advanced Research Projects Agency for
Health), which was created in 2023 to
“take big technical risks that can spark
new biomedical breakthroughs” and
“revolutionize the detections, diagnosis,
mitigation, prevention, treatment and cure
of diseases and health conditions.” Both
former NIH Director Francis Collins and
HHS Secretary Xavier Becerra
supported the agency’s creation, and
Collins described his
vision for ARPA-H as “a DARPA-like
culture at NIH.”
This so-called “therapy”
uses a technology called TIPs (Therapeutic
Interfering Particles), which are
described as “engineered
molecular parasites” that piggyback
on a wild virus. If you get the virus, you
also get these parasites. Once inside an
infected person, the TIPs are supposed to
rapidly multiply, hijacking the resources
the wild virus needs to multiply and
therefore stopping the virus.
Supporters of this
technology claim it will “solve” several
problems with traditional vaccine
delivery, including “behavior barriers”
like noncompliance. Meaning everyone
gets vaccinated—whether they like it or
not.
One of the companies
developing this technology is Autonomous
Therapeutics, led by Dr. Ariel
Weinberger. Autonomous has received
over $15 million
in federal government contracts and
grants, including an ongoing $4.58 million
award from DARPA (a Department of
Defense agency) for “A Rapid-Response
Platform to Develop & Deliver TIPs
Against Respiratory Viral Threats,
Including MERS-CoV” and a $3 million
contract from DARPA for “New
Platform Technologies for Viral and
Therapeutic Evolution Assays” that was
completed in 2022. Dr. Timothy
Notton is the Chief Scientific
Officer at Autonomous and his bio
references his work on “automated
screening platforms (inhalable) LNP
delivery platforms.”
In a recent article,
Ariel gushes:
This next-generation RNA,
which we aim to advance at Autonomous
Therapeutics Inc., is designed to encode
an artificial immune system that
can detect and eliminate every variant
of a viral family. We have developed
encrypted RNA candidates with potential
variant-proof efficacy against a wide
range of pathogens, from coronaviruses
to influenza and RSV. These can be made
inhalable and shielded from human
immune systems to enable safe and
long-term prophylaxis. (Emphasis added.)
The other company working
on similar vaccines, VxBiosciences,
appears to collaborate with the J. David
Gladstone Institutes, led by Dr. Leor
Weinberger—who happens to be Ariel’s
brother. Patents are already established,
such as this one by
Leor and Gladstone Institutes in 2017. In
a 2020 TEDMED talk,
Leor talked about how using viruses would
“convert super-spreaders from spreading
the virus to spreading the therapy.”
HHS issued a $4.8 million
grant to VxBiosciences for
“Autonomously Deploying, Co-evolving
SARS-CoV-2 Antiviral.” The grant was for
engineering “therapeutic molecular
parasites of SARS-CoV-2 that can co-adapt
and transmit among infected hosts … acting
as single-administration therapies that
circumvent compliance issues.”
So, how safe are these
“inhalable therapies”? What could possibly
go wrong with a man-made parasite designed
to self-replicate in your cells and to
transmit without anyone’s knowledge or
consent? Your guess is as good as ours.
But we’d prefer not to find out.
Through its attorneys,
ICAN has already submitted numerous FOIA
requests to DARPA, DOI, the Navy, and NIH
concerning these grants and contracts to
ascertain the truth about who stands to
benefit from these alarming products.
ICAN is already deploying
a legal strategy to ensure that
individuals will never be infected with
engineered viruses and bacteria without
their express consent.
ICAN is also keeping a
close eye on a new COVID-19 nasal vaccine,
called CoviLiv, developed by Codagenix. It
is described as
“designed using the Codagenix platform
technology that re-codes the genetic
material of a virus – converting the virus
from a disease-causing pathogen into a
stable and safe, live-attenuated vaccine.”
No word yet on whether they anticipate
this vaccine could spread from
person-to-person, but they have just
received funding from
the Biomedical Advanced Research and
Development Authority (BARDA).
Stay tuned for more on
this issue as ICAN has instructed its
legal team to dig further into these types
of developing technologies that would
permit involuntary, widespread delivery of
pathogens that result in a complete and
permanent revamping of our God-given
immune systems without requiring any
informed consent. ICAN has also, as noted,
instructed its legal team to deploy a
well-crafted strategy intended to ensure
these technologies cannot be used to
infect anyone without their consent, and
it hopes to bring good news in the near
future about that strategy.
See below for some of
ICAN’s other letters demanding answers
from federal agencies:
To share this legal
update, please use this link: https://icandecide.org/press-release/ican-uncovers-a-potential-next-level-threat-inhalable-self-spreading-vaccines-that-spread-like-a-virus/
